Evidence map›Paper›PMID 37169224›Full record

ArticleAntiviral research2023

Small molecule antiviral compound collection (SMACC): A comprehensive, highly curated database to support the discovery of broad-spectrum antiviral drug molecules.

Holli-Joi Martin, Cleber C Melo-Filho, Daniel Korn, Richard T Eastman, Ganesha Rai, Anton Simeonov, Alexey V Zakharov, Eugene Muratov, Alexander Tropsha

Abstract read
In one paragraph

Article in Antiviral research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Conserved Filovirus Proteins as Targets of Broad-Spectrum Antivirals.bioRxiv : the preprint server for biology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Heli-SMACC: Helicase-targeting SMAll Molecule Compound Collection.bioRxiv : the preprint server for biology · 2024
    Article
  12. Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Holli-Joi MartinUNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Cleber C Melo-FilhoUNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Daniel KornUNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Richard T EastmanDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville, MD, 20850, USA.
Ganesha RaiDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville, MD, 20850, USA.
Anton SimeonovDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville, MD, 20850, USA.
Alexey V ZakharovDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville, MD, 20850, USA. Electronic address: alexey.zakharov@nih.gov.
Eugene MuratovUNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA. Electronic address: murik@email.unc.edu.
Alexander TropshaUNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA. Electronic address: alex_tropsha@unc.edu.

Funding

Research Project 1: Coronavirus antiviral lead development and combination testingU19AI171292 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S · 2022 to 2022
$65.5M
COVID-19: Assay Development, HTS and Drug Repurposing to identify potential therapeutics against SARS-CoV-2ZIATR000457 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI HALL, MATTHEW · 2022 to 2023
$6.7M
Enabling the Accelerated Discovery of Novel Chemical Probes by Integration of Crystallographic, Computational, and Synthetic Chemistry ApproachesR01GM140154 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TROPSHA, ALEXANDER, WILLSON, TIMOTHY M · 2021 to 2024
$2.4M
NIAID NIH HHS U19 AI171292NIGMS NIH HHS R01 GM140154
6 · The paper itself

Abstract

Diseases caused by new viruses cost thousands if not millions of human lives and trillions of dollars. We have identified, collected, curated, and integrated all chemogenomics data from ChEMBL for 13 emerging viruses that hold the greatest potential threat to global human health. By identifying and solving several challenges related to data annotation accuracy, we developed a highly curated and thoroughly annotated database of compounds tested in both phenotypic and target-based assays for these viruses that we dubbed SMACC (Small Molecule Antiviral Compound Collection). The pilot version of the SMACC database contains over 32,500 entries for 13 viruses. By analyzing data in SMACC, we have identified ∼50 compounds with polyviral inhibition profile, mostly covering flavi- and coronaviruses. The SMACC database may serve as a reference for virologists and medicinal chemists working on the development of novel BSA agents in preparation for future viral outbreaks. SMACC is publicly available at https://smacc.mml.unc.edu.

Indexed as

Coronavirus InfectionsVirusesAntiviral AgentsDatabases, FactualHumansAntiviral AgentsAntiviral drug discoveryBroad-spectrumDatabaseDrug repurposing

Identifiers

PMID37169224
PMCPMC11069349

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.